









FDA Liaison
For our non-U.S. clients or those who do not have extensive regulatory
affairs departments, Swiftwater Group provides FDA representation as an
agent (non-U.S. companies) or as the regulatory liaison for all communications
and submissions with FDA.
Regulatory Strategy Development
Often our clients have a product for which the regulatory path is unclear.
Swiftwater Group provides assistance in reviewing the product, selecting
appropriate indications, and evaluating other contributing factors to help
our clients develop the optimal regulatory strategy.
Preparation of Regulatory Submissions
Swiftwater Group can independently prepare all regulatory documents on behalf
of our clients:
- Pre-IND briefing documents
- Drug Master Files (DMF)
- Investigational New Drug Applications (IND)
- New Drug Applications (NDA)
- - 505 (j)
- - 505 (b)(1)
- - 505 (b)(2)
- Supplemental New Drug Applications (sNDA)
- Common Technical Document (CTD)
Regulatory Operation Services
As a follow-on service to developing a regulatory strategy, Swiftwater Group
can integrate into the client’s organization and provide the necessary
regulatory expertise throughout the product development process. This,
in essence, is the combination of all the previously described regulatory
services into one turnkey offering.